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SUMMARY

Alport syndrome, a disease of kidney, ear, and eye, is caused by pathogenic variants in the COL4A3, COL4A4, or COL4A5 genes encoding collagen a3a4a5(IV) of
basement membranes. Collagen IV chains that are truncated due to nonsense variants/premature termination codons (PTCs) cannot assemble into heterotrimers
or incorporate into basement membranes. To investigate the feasibility of PTC
readthrough therapy for Alport syndrome, we utilized two NanoLuc reporters
in transfected cells: full-length for monitoring translation, and a split version for
assessing readthrough product function. Full-length assays of 49 COL4A5
nonsense variants identified eleven as susceptible to PTC readthrough using
various readthrough drugs. In split-NanoLuc assays, the predicted missense
a5(IV) readthrough products of five nonsense mutations could heterotrimerize
with a3(IV) and a4(IV). Readthrough was also observed in kidney cells from an engineered Col4a5 PTC mouse model. These results suggest that readthrough therapy is a feasible approach for a fraction of patients with Alport syndrome.
INTRODUCTION
Alport syndrome is a hereditary kidney glomerular disease with eye and inner ear defects characterized by
glomerular basement membrane (GBM) abnormalities leading to progressive glomerulosclerosis and kidney failure (Hudson et al., 2003). Pathogenic variants in either the COL4A3 (Morrison et al., 1991a, 1991b),
COL4A4 (Mochizuki et al., 1994) or COL4A5 (Barker et al., 1990) genes encoding the type IV collagen a3, a4,
and a5 chains, respectively, cause Alport syndrome. All three chains are necessary to form a functional type
IV collagen a3a4a5 network. The chains assemble inside cells into a3a4a5 heterotrimers (protomers), which
are secreted into the extracellular space (Gunwar et al., 1998), where they polymerize to build a basement
membrane with other components such as laminins, nidogen, and heparan sulfate proteoglycans (Miner,
2011).
The lack or reduction of type IV collagen a3a4a5 in Alport syndrome eventually leads to GBM abnormalities
including thinning, thickening, and splitting. Current standard-of-care therapy uses renin-angiotensin system inhibitors such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
Though they delay progression to kidney failure, they do not cure Alport syndrome (Gross et al., 2003,
2020; Yamamura et al., 2020b). In contrast, development of methods to fix the pathogenic GBM abnormalities compositional, structural, and functional could cure Alport syndrome or overcome the limitations of
current treatments.
One of the potential barriers to the treatment of Alport syndrome using a GBM repair approach is the
requirement that the abnormal GBM composed of collagen IV a1a1a2 be able to incorporate a3a4a5. Genetic rescue experiments in a Col4a3-null Alport syndrome mouse model has shown that postnatal induction of COL4A3 production in podocytes, the glomerular cells that normally synthesize the collagen IV
a3a4a5 network, enables a3a4a5 trimer synthesis, secretion, and incorporation into the Alport GBM, which
attenuates loss of kidney function (Lin et al., 2014). This study shows that restoration of the normal type IV
collagen a3a4a5 network in the Alport GBM is a feasible approach toward a cure.
In the present study, we focused on chemical-induced restoration of COL4A5 expression in COL4A5
nonsense variant types of Alport syndrome. Nonsense variants resulting in premature termination codons
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(PTCs) account for about 6% of Alport syndrome cases (Savige et al., 2016). Type IV collagen chains have a
C-terminal NC1 domain that is essential for assembly of heterotrimers inside cells and for network formation in the GBM. Truncated a3, a4, a5 chains without an intact NC1 domain due to PTCs cannot form trimers
or polymerize in the GBM (Sundaramoorthy et al., 2002). Therefore, achieving full-length protein expression is a potential therapy for Alport syndrome due to nonsense variants.
Small molecule-based PTC readthrough therapy has been well studied in other genetic diseases such as
cystic fibrosis (Crawford et al., 2021; Du et al., 2006), Duchenne muscular dystrophy (Crawford et al.,
2020; Kayali et al., 2012), and inherited skin disorders (Lincoln et al., 2018; Woodley et al., 2017). G418,
an aminoglycoside class antibiotic, is the most studied drug that induces PTC readthrough. Aminoglycosides bind to prokaryotic ribosomes and inhibit protein synthesis in Gram-negative bacteria. In addition to
their affinity for prokaryotic ribosomes, aminoglycosides are known to bind to eukaryotic ribosomes and
induce PTC readthrough of nonsense variants by enabling near-cognate aminoacyl-tRNAs to recognize
PTCs (Roy et al., 2015). Since the discovery of aminoglycoside-induced PTC readthrough, it has been shown
that PTC readthrough can be induced by various aminoglycosides (Du et al., 2006; Friesen et al., 2018; Shulman et al., 2014). Although aminoglycoside-mediated PTC readthrough has the advantages of being well
studied and highly efficient, high doses can cause nephrotoxicity and ototoxicity. To overcome these limitations, structurally designed aminoglycosides with reduced nephrotoxicity and ototoxicity that maintain
readthrough activity have been developed (Shulman et al., 2014; Xue et al., 2014). In addition, non-aminoglycoside PTC readthrough compounds have been identified by high-throughput library screening (Du
et al., 2009; Kayali et al., 2012), and some have been chemically modified to improve activity (Hamada
et al., 2019; Taguchi et al., 2012, 2017). In addition, several compounds have been found to enhance the
activity of PTC readthrough compounds, allowing the use of reduced doses of aminoglycosides and
thus reduced toxicity (Baradaran-Heravi et al., 2016; Ferguson et al., 2019).
With these technological advances, PTC readthrough-based therapy has become a realistic option. However, whether nonsense readthrough therapy is applicable to Alport syndrome is unexplored. Here, we
tested the feasibility of PTC readthrough therapy for X-linked Alport syndrome by generating a NanoLuc-based translation reporter system to evaluate which COL4A5 nonsense variants are susceptible to
readthrough therapy. Forty-nine nonsense variants reported in patients with Alport syndrome were tested,
and 11 of them were highly sensitive to aminoglycoside-mediated PTC readthrough. Moreover, we found
that designer aminoglycoside and non-aminoglycoside PTC readthrough drugs with reduced nephrotoxicity and ototoxicity induced synthesis of full-length PTC readthrough-sensitive variants. Also, PTC readthrough enhancer compounds potentiated aminoglycoside-mediated PTC readthrough. These results
contribute important basic knowledge regarding the feasibility of PTC readthrough therapy in Alport syndrome and suggest that a fraction of patients should benefit from it.

RESULTS
Development of a NanoLuc-based COL4A5 translation reporter system
The efficacy of aminoglycoside-induced PTC readthrough varies greatly from variant to variant (Lincoln
et al., 2018). At least, 76 COL4A5 nonsense variants have been reported in patients with X-linked Alport
syndrome, accounting for 6% of the known variants (Savige et al., 2016). Therefore, determining which
nonsense variants are susceptible to PTC readthrough is a crucial first step toward clinical application.
To evaluate the sensitivity of COL4A5 nonsense variants to PTC readthrough in a high-throughput system,
we generated a COL4A5-NanoLuc reporter plasmid by in-frame fusion of NanoLuc to the COOH-terminus
of COL4A5 (Figure 1A). Introduction of a PTC into the COL4A5-NanoLuc cDNA leads to synthesis of truncated protein without the COOH-terminal NanoLuc, so luminescence is not produced. In this reporter system, it is assumed that a small molecule compound such as an aminoglycoside will promote PTC readthrough, leading to synthesis of a full-length protein and production of luminescence.
First, we introduced a pathogenic nonsense variant, R1563X, into the COL4A5-NanoLuc cDNA to see if we
could detect PTC readthrough in the presence of G418, which is known to have high readthrough activity
and is considered the gold standard PTC readthrough drug in vitro. G418 increased luminescence in
HEK293 cells expressing COL4A5-R1563X-NanoLuc to a level that was 20%–30% of that of WT (Figure 1B).
Moreover, to show that the PTC readthrough was not artifactually related to the presence of the NanoLuc
RNA sequence in the transcript, we investigated whether G418 could induce PTC readthrough of COL4A5R1563X mRNA, using COL4A5-R1563X-DNanoLuc (Figure 1C). Immunoblot analysis showed G418 induced
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Figure 1. Development of a luciferase-based screening platform for testing PTC readthrough of COL4A5
nonsense variants
(A) Schematic representation of the NanoLuc (Nluc) luciferase-based COL4A5 PTC readthrough reporter construct. Nluc
was fused in-frame to the 3’ end of the COL4A5 cDNA. Translation of full-length COL4A5 produces a fused functional
Nluc that generates luminescence, but truncation of COL4A5 translation due to a PTC results in no luminescence.
(B) Luminescence was measured in cell lysates from HEK293 cells transfected with CMV-COL4A5-WT- and R1563XNanoLuc plasmids and HSV-TK-Luc2 (firefly luciferase) for normalization. G418 treatment induced PTC readthrough. The
box extends from the 25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed
using Student’s t test (n = 4). ***, p < 0.005; ****, p < 0.001 vs. non-treated.
(C) Schematics of NanoLuc-tagged (Nluc) and non-tagged (DNluc) COL4A5 expression constructs.
(D) Immunoblots of intracellular-Nluc-tagged or non-tagged COL4A5 products in HEK293 cells treated with G418 for 24
h. Full-length COL4A5 was detected by COL4A5 NC1 domain antibody (H52), and anti-Vinculin was used as loading
control. G418 induced PTC readthrough of COL4A5-R1563X in both NanoLuc-tagged and non-tagged COL4A5expressing cells. RLU, relative light units

PTC readthrough in HEK293 cells expressing either COL4A5-R1563X-NanoLuc or COL4A5-R1563X DNanoLuc (Figure 1D). These results show that the COL4A5-NanoLuc reporter cDNA was sensitive and quantitative enough for monitoring translation of full-length COL4A5 protein in a multi-well plate format.

Screening for PTC readthrough-susceptible COL4A5 nonsense variants
To screen COL4A5 nonsense variants reported in patients with X-linked Alport syndrome for susceptibility
to PTC readthrough, we introduced 49 pathogenic variants individually into the COL4A5-NanoLuc cDNA
reporter by site-directed mutagenesis. Nonsense variants in the collagenous domain that originally encoded Gly were excluded, because if the PTC readthrough product is not Gly, the Gly substitution will likely
impair the function of the PTC readthrough product. Aminoglycoside-induced PTC variants are known to
be influenced by the type of PTC (UGA > UAG > UAA) (Wangen and Green, 2020). Therefore, we selected
all three types of nonsense variants for evaluation. Nonsense variant COL4A5-NanoLuc plasmids were
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Figure 2. Identification of COL4A5 variants susceptible to G418-induced PTC readthrough
(A–C) Luminescence was measured in cell lysates from HEK293 cells co-transfected with either CMV-NanoLuc-fused
COL4A5-WT or the indicated nonsense variants and HSV-TK-Luc2 (firefly) for normalization. Cells expressing one UGA (A),
UAG (B), or UAA (C) COL4A5 nonsense variant cDNA were treated with G418 at the indicated concentrations for 24 h, and
luminescence was measured. G418 induced readthrough of some but not all PTCs. The box extends from the 25th to 75th
percentiles. Data are represented as mean G SEM.
(D) Readthrough efficiency of eleven readthrough-susceptible mutants was compared to WT. The box extends from the
25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed using two-way ANOVA
with Tukey’s multiple comparisons test (n = 4). *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.001 vs. no treatment. RLU,
relative light units

individually transfected into HEK293 cells, and the cells were treated for 24 h with different concentrations
of G418. G418 induced significant PTC readthrough of 40 of the 49 nonsense variants (Figures 2A–2C).
Many of them were statistically significant, but some did not have high PTC readthrough rates. Of the types
of variants that responded to G418, UGA PTCs showed the highest readthrough rates, which agrees with
previous studies. 11 of 49 COL4A5 nonsense variants (C29X, S36X, E130X, C1521X, R1563X, C1567X,
W1594X, S1632X, R1683X, C1684X, and K1689X) showed more than 5-fold induction of PTC readthrough.
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The amount of luminescence produced from these G418-susceptible variants ranged from 10%–30% of the
WT level (Figure 2D).

Gentamicin, an aminoglycoside approved for clinical use, induces PTC readthrough in G418susceptible mutants
Although G418 is one of the most potent readthrough inducers, it is toxic and cannot be used clinically.
Gentamicin is a clinically approved aminoglycoside class antibiotic. Therefore, we investigated whether
gentamicin induced PTC readthrough of the G418-susceptible mutants. COL4A5-NanoLuc reporter
cDNAs with introduced nonsense variants (C29X, S36X, E130X, C1521X, R1563X, C1567X, W1594X,
S1632X, R1683X, C1684X, and K1689X) were transfected into HEK293 cells, and the extent of PTC readthrough induction by gentamicin treatment was quantified by measuring luminescence. Gentamicin significantly induced PTC readthrough of G418 susceptible variants except for COL4A5-K1689X (Figure 3A). The
amount of full-length protein produced with gentamicin-induced readthrough peaked at 5%–10% of WT
for most variants, which was 2–3 times less effective than G418 (Figure 3B). To further investigate PTC readthrough in different cell types, we examined 6 variants highly responsive to PTC readthrough using HeLa,
mouse podocyte, and COS-7 cell lines. As in the experiments with HEK293 cells, wild-type and various
variant plasmids were transfected into each cell line, and G418- and gentamicin-induced PTC readthrough
were evaluated. Similar to HEK293 cells, both G418 and gentamicin induced PTC readthrough in the other
cell types (Figures 3C and 3D).

The efficacy of aminoglycoside-mediated PTC readthrough is dose- and treatment timedependent
To investigate whether aminoglycoside-induced PTC readthrough is treatment time-dependent, we performed long-term treatment experiments using low doses of aminoglycosides on cells expressing
COL4A5-R1563X and -R1683X variants, which were highly responsive to G418 and gentamicin. For longterm treatment, we generated stable COL4A5-R1563X- and COL4A5-R1683X-NanoLuc cDNA-expressing
cells by lentivirus transduction. The degree of PTC readthrough was increased with low-dose G418 treatment in a time-dependent manner (Figures 4A and 4B). The low concentrations of G418 (10 and 30 mg/mL)
slightly increased readthrough, and the moderate concentration (100 mg/mL) dramatically increased fulllength protein synthesis, depending on treatment time. The longer treatment with low concentrations of
gentamicin (30 and 100 mg/mL) did not increase the efficacy of PTC readthrough, but readthrough was
increased at the moderate (300 mg/mL) and high (1000 mg/mL) concentrations (Figures 4C and 4D).

Designer aminoglycoside and non-aminoglycoside readthrough drugs induce PTC
readthrough in the highly susceptible variant COL4A5-R1563X
The potential for successful PTC readthrough therapy with aminoglycosides is dependent on their degrees
of activity, nephrotoxicity, and ototoxicity (Forge and Schacht, 2000). Aminoglycoside toxicity is attributed
to a structural site different from that responsible for PTC readthrough activity (Matt et al., 2012; Shulman
et al., 2014). Therefore, chemical modification has been used to reduce the toxicity of aminoglycosides,
with the aim of reducing toxicity while maintaining readthrough activity. Several aminoglycoside derivatives have been developed and are called designer aminoglycosides (Bidou et al., 2017). The use of PTC
readthrough compounds with non-aminoglycoside structures is also a strategy to reduce toxicity. We
tested a set of next-generation PTC readthrough drugs for efficacy at promoting readthrough of
COL4A5-R1563X, a G418-susceptible mutant (Figure 2A). HEK293 cells expressing the COL4A5-R1563XNanoLuc cDNA were treated with several PTC readthrough drugs for 24 h (Figure 5). Whereas G418 exhibited the highest readthrough activity (Figure 5A), ELX-02, the negamycin analog CDX008, RTC13, and
2,6-diaminopurine (DAP) significantly induced PTC readthrough dose dependently, but RTC14 and
PTC124 did not (Figures 5B–5F and S1A). ELX-02 and DAP showed the highest PTC readthrough activity
among them (Figures 5B and 5F). These results suggest that ELX-02, a designer aminoglycoside, and
DAP, a purine derivative, have PTC readthrough activity for G418-sensitive variants such as R1563X, but
they are expected to exhibit reduced toxicity.

Designer aminoglycoside and non-aminoglycoside PTC-RT drugs are ineffective for the nonG418-susceptible variant COL4A5-G5X
In addition to the G418-susceptible COL4A5-R1563X variant, we also tested whether any next generation
PTC readthrough drugs induced PTC readthrough for the G418 non-susceptible COL4A5-G5X variant
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Figure 3. Gentamicin induces PTC readthrough of G418-susceptible COL4A5 variants
(A) Luminescence was measured in cell lysates from HEK293 cells co-transfected with either CMV-NanoLuc-fused
COL4A5-WT or the indicated nonsense variants and HSV-TK-Luc2 (firefly) for normalization. COL4A5-NanoLuc expressing
cells were treated with gentamicin (as indicated) for 24 h, and luminescence was measured. The box extends from the 25th
to 75th percentiles. Data are represented as mean G SEM.
(B) Readthrough efficiency of eleven susceptible mutants was compared to WT.
(C–E) Luminescence was measured in cell lysates from HeLa cells (C), mouse Podocyte cell line (mPCL) (D), and COS-7
cells (E) co-transfected as in (A). COL4A5-NanoLuc-expressing cells were treated with gentamicin (as indicated) for 24 h,
and luminescence was measured. Readthrough efficiency of six susceptible mutants was compared to WT. The box
extends from the 25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed using
two-way ANOVA with Tukey’s multiple comparisons test (n = 4). *, p < 0.05; ***, p < 0.005; ****, p < 0.001. vs. no treatment.
RLU, relative light units
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Figure 4. PTC readthrough efficiency is dependent on both dose and treatment time
Cells stably expressing NanoLuc fused to COL4A5-R1563X or R1683X and Luc2 (for normalization) were treated with lowdose G418 (A, B) or gentamicin (C, D) for the indicated times. G418 and gentamicin induced PTC readthrough in the
highly susceptible mutants R1563X and R1683X in a dose- and treatment time-dependent manner. The box extends from
the 25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed using two-way
ANOVA with Dunnett’s multiple comparisons test (n = 4). *, p < 0.05; **, p < 0.01; ***, p < 0.005 vs. no treatment

(Figure 5G). Only ELX-02 and RTC13 significantly induced PTC readthrough of COL4A5-G5X (Figures 5B–5L
and S1B). However, the extent of induction was much less than in the case of COL4A5-R1563X (Figures 5B
and 5H). These results indicate that PTC readthrough was not strongly induced in the G418-non-susceptible COL4A5-G5X variant by either ELX-02, which has the same mechanism as G418, or DAP, which exerts its
effects via a different mechanism.

Enhancer drugs improve the efficiency of aminoglycoside-induced PTC readthrough
Several PTC readthrough enhancer compounds have been developed to reduce aminoglycoside-induced
toxicity by lowering the dose required for sufficient PTC readthrough. The PTC readthrough enhancer
CDX5 was identified in a yeast cell-based assay in the presence of the aminoglycoside paromomycin.
The effect of CDX5 was also significant in mammalian cells (Baradaran-Heravi et al., 2016). A more recent
study showed that the antimalarial drug mefloquine potentiated G418-mediated PTC readthrough in
mammalian cells (Ferguson et al., 2019). Here, we investigated whether readthrough enhancers potentiate
aminoglycoside-mediated PTC readthrough in the G418-susceptible COL4A5-R1563X and non-susceptible COL4A5-G5X variants. Mefloquine and CDX5 derivatives potentiated both G418- and gentamicinmediated PTC readthrough of COL4A5-R1563X (Figures 6A and 6B). On the other hand, only mefloquine
potentiated both G418 and gentamicin-mediated PTC readthrough of COL4A5-G5X (Figures 6C and 6D).
Although aminoglycoside-mediated PTC readthrough of COL4A5-G5X was enhanced by mefloquine, the
induction was weaker than that for COL4A5-R1563X without enhancers.

Functionality of the possible PTC readthrough products of G418-susceptible mutants
So far, we have evaluated COL4A5 nonsense variants in terms of their susceptibility to PTC readthrough, but whether the resulting protein product is functional or not is also important for therapeutic
applications. PTC readthrough drugs suppress PTC by facilitating the insertion of near-cognate aminoacyl-tRNAs into the ribosomal-A site during protein translation. Therefore, the readthrough product is
often a full-length protein with an incorrect amino acid at the PTC. If such a substitution impairs the
function of the protein, it may be difficult to rescue the variant phenotype even if a full-length protein
is produced.
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Figure 5. Designer aminoglycoside and non-aminoglycoside PTC readthrough drugs induce PTC readthrough of the highly susceptible variant
COL4A5-R1563X
(A–F) Luminescence was measured in cell lysates from HEK293 cells co-transfected with CMV-NanoLuc-fused COL4A5-R1563X plasmid and HSV-TK-Luc2
(firefly) for normalization. COL4A5-R1563X-NanoLuc-expressing cells were treated with serial dilutions of the indicated drugs. ELX-02, RTC13, and DAP
significantly induced PTC readthrough of COL4A5-R1563X. The box extends from the 25th to 75th percentiles. Data are represented as mean G SEM.
(G–L) Luminescence was measured in cell lysates from HEK293 cells co-transfected with CMV-NanoLuc-fused COL4A5-G5X plasmid and HSV-TK-Luc2
(firefly) for normalization. COL4A5-G5X-NanoLuc-expressing cells were treated with serial dilutions of the indicated drugs. ELX-02 and RTC13 significantly
induced readthrough of COL4A5-G5X. However, as with the G418-mediated readthrough of COL4A5-G5X, the efficiency was lower than that of COL4A5R1563X. The box extends from the 25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed using one-way ANOVA
with Dunnett’s multiple comparisons test (n = 4). *, p < 0.05; ***, p < 0.005 vs. no treatment

To begin to investigate whether the PTC readthrough products from G418-susceptible variants are functional, we utilized a split-NanoLuc-based collagen IV a3a4a5 heterotrimer formation assay. This platform
assays a3a4a5 heterotrimer formation by measuring the luminescence produced by the proximity of NanoLuc fragments fused to the ends of COL4A3 and COL4A5 that are brought together during the formation of
COL4A3/4/5 heterotrimers (Figure 7A) (Omachi et al., 2018). Most pathogenic COL4A5 missense variants
affect a3a4a5 heterotrimer formation and prevent production of functional collagen IV a3a4a5, which
causes Alport syndrome. Therefore, assessing whether PTC readthrough products can assemble into
a3a4a5 heterotrimers is important for evaluating the feasibility of PTC readthrough therapy.
It is known that during G418-induced PTC readthrough, Arg, Trp, and Cys are inserted for UGA, Tyr and
Gln are inserted for UAA, and Gln is inserted for UAA (Dabrowski et al., 2018). The potential readthrough
products from G418-susceptible COL4A5 variants are shown in Table 1. In several cases, it is possible
that PTC readthrough will result in production of some wild-type protein. To investigate the function
of the mutant readthrough products, all possible missense mutant substitutions were generated by
site-directed mutagenesis and assayed using the C-terminal tagged split NanoLuc-based a3a4a5 heterotrimer assay. The luminescence reflecting heterotrimer formation was significantly decreased intracellularly and extracellularly for some readthrough products from C1521X, R1563X, C1567X, W1594X, R1683X,
and C1684X. On the other hand, all readthrough products from C29X, S36X, E130X, S1632X, and K1689X
retained the ability to form a3a4a5 heterotrimers (Figures 7B and 7C). It should be noted that for Arg (R)
codons mutated to UGA, more than half of the product is the wild-type R (Roy et al., 2016), so a higher
percentage of functional full-length proteins are produced than for Cys (C) to UGA and Trp (W) to UGA
mutants. For C29X, S36X, and E130X, the variants are located close to the N-terminus; thus, in addition to
the C-terminal tag assays (Figure 7A, left), we also evaluated the function of readthrough products using
the N-terminal tag system (Figure 7A, right). The extent of heterotrimer formation for C29X-derived
products was reduced by half, whereas S36X- and E130X-derived products retained their functions (Figure 7D). These results indicate that inducing PTC readthrough is a valid approach for a subset of COL4A5
nonsense variants.

Aminoglycosides induced PTC readthrough of Col4a5-R1563X in primary kidney cells derived
from mutant mice
Although we evaluated PTC readthrough in cell systems overexpressing mutant cDNAs, our ultimate goal
is to induce PTC readthrough of nonsense mutant mRNA derived from endogenous COL4 genes. There are
two strains of mouse models for Alport syndrome that carry a Col4a5 nonsense mutation: the Col4a5-G5X
mouse (Rheault et al., 2004) and the Col4a5-R471X mouse (Hashikami et al., 2019). Our cell-based assay
identified G5X as a non-responsive nonsense variant. Furthermore, R471X is not conserved in the human
genome (human: Q471X (UAA), mouse R471X (UGA)). Therefore, we generated an Alport syndrome mouse
model carrying the Col4a5-R1563X nonsense mutation, a variant susceptible to PTC readthrough in cellbased assays (Figures 1A and 2A). We designed a specific single guide (sg) RNA targeting near the codon
of interest. Then, the sgRNA, Cas9 protein, and a single-stranded DNA oligonucleotide carrying the mutation were introduced into zygotes by electroporation (Figure 8A) to produce founders. Because the
Col4a5-R1563X variant is located near an exon-intron junction, we assayed for splicing abnormalities by
RT-PCR and Sanger sequencing using RNA from Col4a5-R1563X mice. This assay revealed no splicing abnormalities and showed that the targeted mutation was correctly inserted (Figure 8B). The absence of type
IV collagen a3a4a5 in the GBM of Col4a5-R1563X mice was confirmed by immunofluorescence (Figure 8C).
To directly investigate the feasibility of bypassing an endogenous Col4a5 nonsense variant by PTC readthrough, we studied primary kidney cells from Col4a5 nonsense mutant mice. We investigated COL4A5
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Figure 6. PTC readthrough enhancer drugs increase the efficiency of readthrough
Luminescence was measured in cell lysates from HEK293 cells co-transfected with CMV-NanoLuc-fused COL4A5-R1563X
(A, B) or -G5X (C, D) and HSV-TK-Luc2 (firefly) for normalization. Cells were treated with the indicated doses of G418 (A, C)
or gentamicin (B, D) supplemented with the indicated readthrough enhancer compounds at 20 mM, and the efficiency of
readthrough was compared to WT. Mefloquine and CDX-288 enhanced the readthrough efficacy of both G418 and
gentamicin in COL4A5-R1563X-expressing cells. CDX6-180 slightly enhanced gentamicin-mediated PTC readthrough of
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Figure 6. Continued
COL4A5-R1563X. In contrast to R1563X, only mefloquine enhanced readthrough of COL4A5-G5X. The box extends
from the 25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed using twoway ANOVA with Dunnett’s multiple comparisons test (n = 4). *, p < 0.05; **, p < 0.01; ***, p < 0.005 vs. no G418 or
gentamicin treatment

protein expression in primary Col4a5-R1563X cells from whole kidney and from isolated glomeruli after
treatment with either G418 or gentamicin for 24 h. To increase intracellular protein abundance, the cells
were co-treated with the ER-Golgi transport inhibitor Brefeldin A so that COL4A5 protein would accumulate. Full-length COL4A5 protein expression was induced in Col4a5-R1563X primary kidney cells and in primary glomerular cells treated with either G418 or gentamicin (Figure 8D). Finally, we compared full-length
protein production using primary kidney cultures from mice carrying Col4a5-R1563X, which is highly susceptible to PTC readthrough, vs. -G5X, which is less susceptible (Figures 1A and 2B). Consistent with our
cell-based assays, we found that G418 and gentamicin induced full-length protein synthesis in R1563X cells
but not in G5X cells (Figure 8E).

DISCUSSION
The goal of this study was to determine the applicability of PTC readthrough therapy in Alport syndrome caused by nonsense variants. Because the susceptibility to PTC readthrough differs greatly
among variants (Bidou et al., 2004; Pranke et al., 2018), the first step would be to determine which variants are susceptible. Because the type IV collagen genes are relatively large with many reported
nonsense variants (Crockett et al., 2010; Savige et al., 2016), we thought it is essential to evaluate a simple reporter system with high throughput to cover most of them. In addition, previous studies have
shown that PTC readthrough activity is affected by the sequences surrounding the nonsense variants
(Stiebler et al., 2014; Wangen and Green, 2020). Therefore, we constructed a reporter using the fulllength COL4A5 cDNA instead of a short cDNA containing the PTC. Because the full-length COL4A5
cDNA itself is about 5 kb, we used NanoLuc as a reporter to construct the fusion gene because of
its small size (513 bp) and high sensitivity (England et al., 2016; Hall et al., 2012). The COL4A5-NanoLuc
reporter cDNA developed in this study allowed us to identify which of 49 tested COL4A5 nonsense variants are susceptible to PTC readthrough. Also, this study showed the efficacy of next generation PTC
readthrough drugs and potentiator compounds that enhance PTC readthrough activity. Finally, to
demonstrate proof of concept for PTC readthrough of an endogenous Col4a5 nonsense variant, we
generated a Col4a5 mutant mouse line with one of the susceptible nonsense variants, Col4a5R1563X. Ex vivo experiments with primary cells showed that aminoglycosides induced PTC readthrough
of endogenous Col4a5-R1563X.
Through comprehensive variant screening, we found that UGA COL4A5 nonsense variants were more
susceptible to aminoglycoside-mediated PTC readthrough than UAG and UAA. This is consistent with previous studies (Bidou et al., 2004). However, as previously reported, not all UGA PTCs showed high susceptibility (Nudelman et al., 2010), and it was reconfirmed that susceptibility varied depending on the variant.
Susceptibility is known to be affected by the surrounding nucleotide sequence. To attempt to determine
whether susceptibility is based on the flanking nucleotide sequence, we aligned the cDNA sequences
around PTCs that were G418-susceptible and compared them to those flanking the non-susceptible
PTCs (Figure S2). However, no overt differences between susceptible and non-susceptible sequences
were observed. This suggests that susceptibility is defined by factors other than the peripheral sequence,
such as the location of the variant in the gene. Although more detailed comparative studies are needed,
these results highlight the importance of screening for PTC readthrough using full-length cDNAs rather
than just short cDNA reporters carrying sequence near the PTC.
One limitation of this reporter system is that the presence of nonsense-mediated mRNA decay (NMD)
cannot be taken into account because the mRNA derived from the cDNA does not need to be spliced
and thus does not have the spliced exon-exon junctions that are required for mRNA surveillance (Popp
and Maquat, 2016). mRNAs produced from genes with nonsense variants are partially degraded by
NMD (Trcek et al., 2013). Therefore, promotion of basal readthrough by suppression of NMD is one of
the therapeutic strategies for nonsense variants, but we have not been able to investigate this. However,
because induction of PTC readthrough by NMD inhibition alone is not expected to be very high (Bhuvanagiri et al., 2014), and many aminoglycosides have an activity that inhibits NMD, this limitation is not likely a

iScience 25, 103891, March 18, 2022

11

iScience

ll

Article

OPEN ACCESS

A

C

B

D

12

E

iScience 25, 103891, March 18, 2022

iScience

ll

Article

OPEN ACCESS

Figure 7. Functional analysis of the potential readthrough products from the susceptible COL4A5 variants
(A) Schematic representation of the split NanoLuc-based COL4A3/4/5 trimer formation reporter system. Split NanoLuc fragments (large fragment, Lg; small
fragment, Sm) were fused in-frame to the 30 end of COL4A5 and COL4A3. When COL4A3/4/5 heterotrimers form, split NanoLuc fragments are in close
proximity and acquire the ability to produce luminescence. Luminescence was measured in cell lysates (B) and culture media (C) from HEK293T cells
expressing C-terminal tagged COL4A5-Lg (WT or the indicated mutants), COL4A3-Sm, and non-tagged COL4A4. HSV-TK-Luc2 (firefly) was included for
normalization. In similar studies, luminescence was measured in cell lysates (D) and culture media (E) from HEK293Tcells expressing the analogous Nterminus-tagged proteins. The box extends from the 25th to 75th percentiles. Data are represented as mean G SEM. Statistical analysis was performed using
one-way ANOVA with Dunnett’s multiple comparisons test (n = 4). *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.001 vs. WT COL4A5

serious problem, but it should be taken into account to accurately determine PTC readthrough activity
in vivo. To overcome this limitation, CRISPR/Cas9-mediated genome editing could be used to create cells
with point mutants in endogenous genes (Anzalone et al., 2020), which would allow the evaluation of PTC
readthrough activity under the same conditions as in vivo. However, the throughput of this method would
be very low, and it is not suitable for evaluating a large number of variants as in the present study.
In addition to defining the readthrough susceptibility of each variant, it is also important to determine whether
the possible PTC readthrough products are functional (Brumm et al., 2012). To investigate this, we used splitNanoLuc-based type IV collagen a3a4a5 heterotrimer formation assays to identify which G418-induced fulllength but missense variant proteins are functional. Some variants had high readthrough activity but may
lose function when a different amino acid from the original is inserted. Many of the variants are located in
the COL4A5 C-terminal NC1 domain, which is essential for a5 to form a functional triple-helical structure
with other a-chains (Sundaramoorthy et al., 2002). Therefore, structural changes in the protein due to missense
variants are likely to interfere with the formation of the correct NC1 complex. However, the results showed that
the wild-type S1632 and K1689 residues are not required to form the NC1 complex (Figures 8B and 8C). Also,
C29 and S36 in the N-terminal 7S domain and E130 in the N-terminal collagenous domain could be replaced
without total inhibition of heterotrimer assembly (Figures 8B–8E). The results suggest that C29 substitution did
not impact NC1 complex formation, but partially affected assembly at the N-terminus. This is consistent with
the importance of the Cys residue in the 7S domain for disulfide bond formation to other a-chains (Risteli et al.,
1980). Using two different assay systems, the PTC readthrough reporter assay and the a3a4a5 heterotrimer
assay, we identified several variants that seem truly susceptible to PTC readthrough therapy.
The biggest challenge in PTC readthrough therapy is the toxicity of drugs used at high concentrations for
long periods of time to induce synthesis of enough full-length proteins to impact phenotypes. Treatment
with high concentrations of aminoglycosides involves the risk of nephrotoxicity and ototoxicity. Fortunately, these issues are being addressed by the development of new PTC readthrough drugs, including
new aminoglycoside derivatives (Friesen et al., 2018; Shulman et al., 2014) and non-aminoglycoside compounds (Du et al., 2009; Hamada et al., 2019; Trzaska et al., 2020). Regarding this point, we showed that an
aminoglycoside derivative and non-aminoglycoside PTC readthrough drugs induced PTC readthrough in
the G418-susceptible COL4A5-R1563X variant (Figure 5). In addition, from the viewpoint specific to Alport
syndrome, type IV collagen a3a4a5 that incorporates into the GBM should be stable for a long period of
time (Liu et al., 2020). This means that once enough type IV collagen a3a4a5 is induced by PTC readthrough
and incorporated into the GBM, continuous treatment should not be necessary, though intermittent treatments would likely be required. This suggests that Alport syndrome could be especially suitable for PTC
readthrough therapy.
In summary, the present study proposes PTC readthrough as a personalized therapeutic approach for Alport
syndrome based on the susceptibility of specific pathogenic nonsense variants to readthrough. Susceptible
variants account for about 10% of all nonsense variants, which amounts to <1% of all variants reported in Alport
syndrome. Based on the overall frequency of Alport syndrome, the number of patients who could benefit from
PTC readthrough therapy is estimated to be 8963 (Table S1). The forms of Alport syndrome caused by
nonsense variants, which are classified as truncating variants, are typically more severe than the non-truncating
forms, which are usually caused by missense variants. Therefore, the successful development of PTC readthrough therapy would have significant benefits for patients with the most severe forms of Alport syndrome.
With various innovations such as the development of designer aminoglycosides and non-aminoglycoside PTC
readthrough compounds, PTC readthrough therapy has become an increasingly realistic approach. In fact,
some such compounds are in clinical trials for nephropathic cystinosis (ClinicalTrials.gov Identifier:
NCT04069260) and cystic fibrosis (ClinicalTrials.gov Identifier: NCT04126473, NCT02139306). The present
study provides important information on PTC readthrough-susceptible COL4A5 variants, and it is hoped
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Table 1. Potential PTC readthrough products from G418-susceptible mutants

Nonsense mutation

PTC readthrough
products

Predicted ratio
(Dabrowski et al., 2018)

Structural location

C29X (UGA)

C29R

64.5 G 11.8%

7S

C29C (WT)

17.7 G 8.0%

C29W

17.9 + 6.8%

S36X (UGA)

E130X (UAA)

C1521X (UGA)

R1563X (UGA)

C1567X (UGA)

W1594X (UGA)

S1632X (UGA)

R1683X (UGA)

C1684X (UGA)

K1689X (UAA)

S36R

64.5 G 11.8%

S36C

17.7 G 8.0%

S36W

17.9 + 6.8%

E130Y

47.9 G 14.1%

E130Q

52 G 14.2%

C1521R

64.5 G 11.8%

C1521C (WT)

17.7 G 8.0%

C1521W

17.9 + 6.8%

R1563R (WT)

64.5 G 11.8%

R1563C

17.7 G 8.0%

R1563W

17.9 + 6.8%

C1567R

64.5 G 11.8%

C1567C (WT)

17.7 G 8.0%

C1567W

17.9 + 6.8%

W1594R

64.5 G 11.8%

W1594C

17.7 G 8.0%

W1594W (WT)

17.9 + 6.8%

S1632R

64.5 G 11.8%

S1632C

17.7 G 8.0%

S1632W

17.9 + 6.8%

R1683R (WT)

64.5 G 11.8%

R1683C

17.7 G 8.0%

R1683W

17.9 + 6.8%

C1684R

64.5 G 11.8%

C1684C (WT)

17.7 G 8.0%

C1684W

17.9 + 6.8%

K1689Y

0.8 G 7.0%

K1689Q

86.5 G 8.3%

7S

Collagenous (Gly-X-Y)

NC1

NC1

NC1

NC1

NC1

NC1

NC1

NC1

that new gene-edited mouse models of Alport syndrome carrying the analogous variants in Col4a5 will facilitate proof-of-concept PTC readthrough studies in vivo in the near future.

Limitations of the study
Although we attempted to do so in Table S1, it is difficult to estimate how many patients might actually
benefit from PTC readthrough therapy based on the present study alone. G418 induced statistically significant PTC readthrough of 40 of the 49 nonsense variants tested (Figure 2A); 11 were induced > 5-fold, and
17 were induced 2- to 3-fold. These results are from a 24 h treatment, but the actual treatment in vivo would
be longer term, so the induced protein is expected to accumulate in the GBM over time. In fact, in cellbased assays, prolonging the treatment time by 2–3 days resulted in a significant increase in PTC readthrough product (Figure 4). To determine what percent of variants are amenable to PTC readthrough therapy in a clinically meaningful way, it will be necessary to investigate what level of protein induction is
required to produce a therapeutic effect in future studies using mouse models. According to the results
of exon skipping therapy in a mouse model of Alport syndrome (Yamamura et al., 2020a), the induction
of only a small amount of type IV collagen a3a4a5 in the GBM showed significant therapeutic effects, so
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Figure 8. Ex vivo experiments with Col4a5-R1563X mice shows PTC readthrough of an endogenous nonsense
variant
(A) Schematic diagram showing gRNA and ssODN targeting sites to generate the Col4a5-R1563X mutant via CRISPR/
Cas9.
(B) Schematic diagram shows the R1563X codon (TGA) split between exons 50 and 51. The gel image shows RT-PCR
products amplified from exon 49 to 52 from WT and Col4a5-R1563X kidney RNA. No splicing abnormalities were
detected. Sanger sequencing shows the desired R1563X nonsense mutation.
(C) Immunofluorescence staining for COL4A5 protein shows its absence from Col4a5-R1563X mouse kidney. Scale bar:
100 mm.
(D) Immunoblot images of COL4A5 protein shows PTC readthrough of the endogenous Col4a5-R1563X. G418 and gentamicin
induced full-length protein expression (*) in Col4a5-R1563X primary kidney cells (left) and glomerular cells (right).
(E) Comparison of PTC readthrough efficiency between Col4a5-R1563X and -G5X primary kidney cells. G418 and
gentamicin induced PTC readthrough in R1563X cells but not in G5X cells. This is consistent with cell-based PTC
readthrough experiments. Statistical analysis was performed using two-way ANOVA with Dunnett’s multiple comparisons
test (n = 3). *, p < 0.05; **, p < 0.01; vs. no G418 or gentamicin treatment
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perhaps even low rates of PTC readthrough may, over time, have therapeutic effects. Further studies are
clearly necessary before this therapy can be translated into clinical practice, both in terms of readthrough
efficiency and toxicity of long-term treatment.
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Rat IgG anti-COL4A5 NC1 monoclonal antibody (clone H52)

Chondrex

Cat# 7077

Rat IgG anti-COL4A5 NC1 monoclonal antibody (clone H53)

Chondrex

Cat# 7078

Antibodies

Mouse IgG1 anti-Vinculin monoclonal antibody (clone 7F9)

Santa Cruz

Cat# sc-73614; RRID:AB_1131294

Rabbit IgG anti-Laminin-111 polyclonal antibody

Sigma-Aldrich

Cat# L9393; RRID:AB_477163

Goat IgG anti-Rat IgG secondary antibody, Alexa 488

Invitrogen

Cat# A-11006; RRID:AB_2534074

Goat IgG anti-Rabbit IgG secondary antibody, Alexa 594

Invitrogen

Cat# A-11012; RRID:AB_141359

Chemicals, peptides, and recombinant proteins
G418 disulfate solution (50 mg/mL)

Sigma-Aldrich

Cat# G8168

RTC13

Sigma-Aldrich

Cat# SML1725

2,6-Diaminopurine (DAP)

Sigma-Aldrich

Cat# 247847

Brefeldin A

Sigma-Aldrich

Cat# B6542

Gentamicin (50 mg / mL)

Life Technologies

Cat# 15750-060

ELX-02

Sussex Research

N/A

Negamycin analog CDX008

WuXi AppTec

N/A

RTC14

ChemBridge

Cat# 5311257

PTC124

Cayman Chemical

Cat# 16758

Lipofectamine 3000 Transfection Reagent

Invitrogen

Cat# L3000001

FuGENE 6 Transfection Reagent

Promega

Cat# E2691

X-tremeGENE 360 Transfection Reagent

Roche

Cat# XTG360-RO

Nano-Glo Dual-Luciferase Reporter Assay System

Promega

Cat# N1620

SuperSignal West Pico Chemiluminescent Substrate

Thermo Scientific

Cat# 34580

Critical commercial assays

Amersham ECL select Western Blotting Detection Reagent

Cytiva

Cat# RPN2235

Pierce BCA Protein Assay Kit

Thermo Scientific

Cat# 23225

Experimental models: Cell lines
Human: HEK293 cells

ATCC

Cat# CRL-1573; RRID: CVCL_0045

Human: 293T cells

ATCC

Cat# CRL-3216; RRID: CVCL_0063

Human: HeLa cells

ATCC

Cat# CCL-2; RRID: CVCL_0030

Mouse: podocyte cells

Schiwek et al., 2004

N/A

Monkey: COS-7 cells

ATCC

Cat# CRL-1651; RRID: CVCL_0224

Experimental models: Organisms/strains
Mouse: Col4a5<tm1Yseg>/<G5X>

The Jackson Laboratory

Cat# 006183; RRID:MGI:3610502

Mouse: Col4a5<R1563X>

This study

N/A

sgRNA for R1563X production, see STAR Methods

This study

N/A

ssODN for R1563X production, see STAR Methods

This study

N/A

Primers for the site-directed mutagenesis, see Table S1

This study

N/A

Primers for splicing analysis in

This study

N/A

This study

N/A

Oligonucleotides

Col4a5-R1563X mouse, see STAR Methods
Primers for Sanger sequencing see STAR Methods
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Promega

Cat# N1361
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This study

N/A
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N/A

pNLF1-C-COL4A5-Nluc: C29X
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N/A

pNLF1-C-COL4A5-Nluc: Y30X
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This study

N/A

pNLF1-C-COL4A5-Nluc: S1071X

This study

N/A

pNLF1-C-COL4A5-Nluc: K1097X
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This study

N/A

pNLF1-C-COL4A5-Nluc: K1320X

This study

N/A

pNLF1-C-COL4A5-Nluc: Q1383X

This study

N/A

pNLF1-C-COL4A5-Nluc: Q1499X

This study

N/A

pNLF1-C-COL4A5-Nluc: Q1501X

This study

N/A

pNLF1-C-COL4A5-Nluc: C1521X

This study

N/A

pNLF1-C-COL4A5-Nluc: Y1543X

This study

N/A

pNLF1-C-COL4A5-Nluc: W1538X

This study

N/A

pNLF1-C-COL4A5-Nluc: R1563X

This study

N/A

pNLF1-C-COL4A5-Nluc: C1567X

This study

N/A

pNLF1-C-COL4A5-Nluc: E1574X

This study

N/A

pNLF1-C-COL4A5-Nluc: W1594X

This study

N/A

pNLF1-C-COL4A5-Nluc: Y1597X

This study

N/A
(Continued on next page)

20

iScience 25, 103891, March 18, 2022

iScience

ll

Article

OPEN ACCESS

Continued

REAGENT or RESOURCE

SOURCE

IDENTIFIER

pNLF1-C-COL4A5-Nluc: S1632X

This study

N/A

pNLF1-C-COL4A5-Nluc: S1661X

This study

N/A

pNLF1-C-COL4A5-Nluc: R1674X

This study

N/A

pNLF1-C-COL4A5-Nluc: R1683X

This study

N/A

pNLF1-C-COL4A5-Nluc: C1684X

This study

N/A

pNLF1-C-COL4A5-Nluc: Q1685X

This study

N/A

pNLF1-C-COL4A5-Nluc: K1689X

This study

N/A

pLVSIN-Puro Human COL4A5-Nluc: WT

This study

N/A

pLVSIN-Puro Human COL4A5-Nluc: R1563X

This study

N/A

pLVSIN-Puro Human COL4A5-Nluc: R1683X

This study

N/A

pLVSIN-Hygro Luc2

This study

N/A

pFC36K SmBiT TK-Neo Human COL4A3

Omachi et al., 2018

N/A

pLVSIN-Puro Human COL4A4

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: WT

Omachi et al., 2018

N/A

pFC34K LgBiT TK-Neo Human COL4A5: G869R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C29R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C29W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: S36R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: S36C

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: S36W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: E130Q

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C1521R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C1521W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: R1563C

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: R1563W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C1567R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C1567W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: W1594R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: W1594C

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: S1632R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: S1632C

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: S1632W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: R1683C

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: R1683W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C1684R

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: C1684W

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: K1689Y

This study

N/A

pFC34K LgBiT TK-Neo Human COL4A5: K1689Q

This study

N/A

pFN35K SmBiT TK-Neo Human COL4A3

Omachi et al., 2018

N/A

pFN33K LgBiT TK-Neo Human COL4A5: WT

Omachi et al., 2018

N/A

pFN33K LgBiT TK-Neo Human COL4A5: C29R

This study

N/A

pFN33K LgBiT TK-Neo Human COL4A5: C29W

This study

N/A

pFN33K LgBiT TK-Neo Human COL4A5: S36R

This study

N/A

pFN33K LgBiT TK-Neo Human COL4A5: S36C

This study

N/A

pFN33K LgBiT TK-Neo Human COL4A5: S36W

This study

N/A

pFN33K LgBiT TK-Neo Human COL4A5: E130Q

This study

N/A
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pMD2.G

Addgene

#12259

psPAX2

Addgene

#12260

ImageJ

National Institutes of Health

https://imagej.nih.gov/ij/

GraphPad Prism (version 9)

N/A

https://www.graphpad.com/

Image Lab Software (Version 6.01)

Bio-Rad

Software and algorithms

scientific-software/prism/
https://www.bio-rad.com/en-us/
product/image-lab-software?ID=KRE6P5E8Z

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to the lead contact, Dr.
Jeffrey H. Miner (minerj@wustl.edu).

Materials availability
Reagents generated in this study are available from the lead contact under Material Transfer Agreements.

Data and code availability
 This paper does not contain any datasets and codes.
 Any additional information required to reanalyze the data reported in this paper is available from the
lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture and cell lines
Human embryonic kidney (HEK) 293 cells (ATCC CRL-1573), 293T cells (ATCC CRL-3216) cells and COS-7
cells (CRL-1651) were maintained at 37 ºC, 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% heat inactivated fetal bovine serum and penicillin-streptomycin. HeLa cells
(ATCC-CCL-2) were maintained at 37 ºC, 5% CO2 in Minimum Essential Medium supplemented with 10%
heat inactivated fetal bovine serum and penicillin-streptomycin. The mouse podocyte cell line (mPCL)
(Schiwek et al., 2004) was maintained at 33 ºC, 5% CO2 in RPMI-1640 supplemented with 10% heat
inactivated fetal bovine serum, penicillin-streptomycin and recombinant interferon-g (100U / mL). For
PTC readthrough experiments, HEK293, HeLa, mPCL and COS-7 cells were used. We did not use 293T cells
for PTC readthrough experiments because 293T cells are G418-resistant. For function tests of the potential
PTC readthrough products by split NanoLuc assay, 293T cells were used. Cells stably expressing cDNAs
were generated by lentivirus infection. Transduced cells were selected by culturing in DMEM with appropriate antibiotics for 2 weeks.

Mouse models
To generate Col4a5-R1563X mice, a single guide RNA (5’-CAGCCATTCATTAGTCGGTA-3’) targeting the
3’ end of Col4a5 exon 50, a single-stranded DNA oligonucleotide with the R1563X mutation (5’-GCTTCAA
GAAATGACTATTCTTACTGGCTTTCCACCCCAGAGCCCATGCCAATGAACATGGAACCCCTGAAGGG
ACAGAGCATCCAGCCATTCATTAGTTGGTAAGGCACTGGTTTAGCTTTGACATTTACCAATTACCCCTT
AGTTTAGCTAGTAAGAAATCAGTGTAAAATGGATAATCCATGATACTCACCCAAGTT-3’), and Cas9 protein were introduced into FVB/NJ zygotes by electroporation. Mutations in the founder mice were analyzed
by deep sequencing after genomic amplification with primers (5’–TCGATTCATCATAGGTACGGCTGG
CAGCTG-3’; 5’-GTAGCACTTGGTCTAAGCTGGATGCATCCC-3’). The RNA splicing pattern and mRNA
sequence were analyzed by RT-PCR with RNA isolated from male Col4a5WT/Y and Col4a5R1563X/Y kidney tissues. The primer sequences were: sense, 5’- aacagaagcaccacaatgcccacgg-3’; anti-sense, 5’ gcatgtccctc
gcccatgacattcg-3’. The splicing pattern between Exons 49 and 52 was determined by agarose gel electrophoresis and by Sanger sequencing. FVB/NJ Col4a5-R1563X mice were backcrossed to C57BL/6J mice for
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at least four generations. Col4a5-G5X mutant mice (Col4a5tm1Yseg, JAX: 006183) were obtained from Yoav
Segal. RT-PCR analysis of kidney RNA showed that this mutation does not impact RNA splicing (Figure S3).
All animal experiments conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Washington University Animal Studies Committee.

METHODS DETAILS
Chemical compounds
G418 disulfate solution (50 mg/mL), RTC13, 2,6-diaminopurine, and Brefeldin A were purchased from
Sigma-Aldrich (catalog no. G8168, SML1725, 247847 and B6542). Gentamicin (50 mg / mL) was purchased
from Gibco, Life Technologies Corporation (catalog no. 15750-060). ELX-02 was synthesized by Sussex
Research. The negamycin analog CDX008 (Figure S1) was synthesized by WuXi AppTec. RTC14 was from
ChemBridge Corporation (catalog no. 5311257). PTC124 was purchased from Cayman Chemical (catalog
no. 16758).

Plasmids
To generate the COL4A5 with C-terminal NanoLuc fusion expression vector, full-length human COL4A5
cDNA was amplified from pEF6-COL4A5-Myc (Omachi et al., 2018), cloned into pNLF1-C [CMV/Hygro] vector (Promega). pLV-BSD COL4A5-LgBiT (C terminal tag), pLV-Hygro COL4A3-SmBiT (C terminal tag), pLVPuro COL4A4, pFN33K-COL4A5-LgBiT (N terminal tag) and pFN35K-COL4A3-SmBiT (N terminal tag) were
used for split NanoLuc luciferase-based COL4A3/4/5 trimer formation assay (Omachi et al., 2018). For all
luciferase assays, pGL4.54 [luc2/TK] (Promega) was used as a co-transfected control vector. The variant
COL4A5 expression vectors used in this study were generated by site-directed mutagenesis as previously
described. Primer sequences are shown in Table S2. The introduced variants were verified by Sanger
sequencing.

Transfection, lentivirus production, infection and treatment
HEK293, HeLa and COS-7 cells were transfected with pNLF1-C-COL4A5-Nluc (WT and mutants) and
pGL4.54 [luc2/TK] plasmids by FuGENE 6 transfection reagent (Promega). mPCL were transfected with
pNLF1-C-COL4A5-Nluc (WT and mutants) and pGL4.54 [luc2/TK] plasmids by X-treamGENE 360 transfection reagent (Roche). Formation of plasmids/FuGENE 6 or X-treamGENE 360 complexes was performed
according to the manufacturer’s instructions. At 48 h after transfection, cells were treated with DMEM containing G418 or other PTC readthrough drugs.
To produce lentivirus, 293T packaging cells were seeded at 5.5-6.0 3 105 cells per wells in DMEM in 6-well
tissue culture plates. Seeded cells were incubated at 37 ºC, 5% CO2 for 20 h. Culture media were changed
to fresh DMEM with 10% heat inactivated fetal bovine serum and transfected with 1 mg of psPAX2 (Addgene: #12260), 100 ng of pMD2.G (Addgene: #12259), and 1 mg of lentivirus transfer vector per well by Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer’s instructions. 24 h after
transfection, culture media were changed to DMEM supplemented with 30% heat inactivated fetal bovine
serum. Lentivirus-containing supernatants were collected after 24 h and filtered with 0.45 mm PVDF or PES
membrane syringe filter unit. HEK293 cells or 293T cells were seeded in filtered lentivirus containing media
supplemented with 8 mg/mL polybrene (Sigma) and cultured for 24 h, then cells were cultured in DMEM
with 10% FBS and the appropriate antibiotics for 2 weeks (Hygromycin; 200-400 mg/mL, Blasticidin:
10 mg/mL, Puromycin 10 mg/mL).

Cell lysis, gel electrophoresis, and immunoblotting
Transfected HEK293 cells were washed twice with ice-cold phosphate buffered 0.9% saline (PBS) and lysed
in RIPA buffer (0.05 M Tris-HCl [pH 7.5], 0.15 M NaCl, 1% v/v Nonidet P-40, 1% w/v Na deoxycholate, and 1%
protease inhibitor cocktail). The cell lysates were centrifuged at 14,000 g for 15 min at 4 C, and clear supernatants were collected. The protein concentration was determined using a bicinchoninic acid kit (Thermo),
and equal amounts of protein lysates were loaded and separated by SDS PAGE, immunoblotted with antiCOL4A5 NC1 antibody (H52, Chondrex) for human COL4A5 cDNA-transfected HEK293 cells, anti-COL4A5
NC1 antibody (H53, Chondrex) for mouse primary cells, and anti-vinculin antibody (7F9, Santa Cruz), and
visualized using Super-Signal West Pico Chemiluminescent Substrate (Thermo) and ECL select Western
Blotting Detection Reagent (Cytiva).
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Luciferase assay
pNLF1-C-COL4A5-NanoLuc and HSV-TK-Luc2 plasmids were transfected into HEK293, HeLa, mPCL and
COS-7 cells. After 48 h, cells were fed with culture media containing the test compounds. At 72 h after transfection, Nano-Glo Dual Luciferase Reporter Assay reagent (Promega) was added, and the luciferase activity
in the cell lysates was measured using a GloMax Navigator system (Promega). All luciferase assays were
conducted in LumiNunc 96-well white plates (Invitrogen). NanoLuc luciferase was normalized by constitutively expressed firefly luciferase.

Immunofluorescence
Kidneys were harvested from anesthetized 1-month-old male Col4a5WT/Y and Col4a5R1563X/Y mice, and unfixed kidneys were immersed in O.C.T. compound (Tissue-Tek, Sakura Finetek) in a Cryomold (Tissue-Tek,
Sakura Finetek) and frozen in liquid nitrogen. Unfixed 7mm frozen sections were blocked with 1% bovine
serum albumin/PBS at room temperature for 1 h. Then, sections were incubated with rat IgG antiCOL4A5 antibody (H53, 1/200) and rabbit IgG anti-laminin-111 antibody (Sigma L9393, 1/200) at room temperature for 2 h. Next, sections were washed with PBS three times and incubated with secondary
antibodies; Alexa 488-anti-Rat-IgG antibody (1/200) and Alexa 594-anti-Rabbit-IgG antibody (1/200) in
PBS containing 1% normal mouse serum at room temperature for 30 min. Sections were washed three times
with PBS, mounted, and observed under a fluorescence microscope.

Ex-vivo experiments with primary kidney cells
Kidneys were removed from anesthetized 1-month-old male Col4a5WT/Y, Col4a5G5X/Y, Col4a5R1563X/Y, and
female Col4a5WT/WT, Col4a5G5X/G5X, and Col4a5R1563X/R1563X mice perfused with PBS. The kidneys were
minced to 1-2 mm2 pieces on ice and digested in 1 mg/mL collagenase and 100U/mL DNase I for
30 min at 37 C. After digestion, they were filtered with a 100mm cell strainer and then centrifuged (200
g, 5 min). The supernatants were removed, and tissue pellets were dissociated with PBS. They were filtered
with a 100mm cell strainer and then centrifuged (200 g, 5 min) again. The supernatants were removed and
tissue pellets were dissociated with cell culture media. Cell suspensions were seeded onto type I collagen
coated tissue culture dishes. Attached cells were maintained at 37 C, 5% CO2 in RPMI-1640 supplemented
with 10% heat inactivated fetal bovine serum and penicillin-streptomycin, insulin, transferrin, and selenium.
After 3 days culture, cells were dissociated with 0.25% trypsin/EDTA and filtered with a 30mm cell strainer
and then centrifuged (200 g, 5 min). Cell pellets were dissociated with culture media and seeded onto type I
collagen coated dishes and used for experiments.
Primary glomerular cells were isolated by a mesh sieving method (Wilson and Stewart, 2012). The kidneys
were removed and minced into 1-2 mm2 pieces on ice. The minced kidneys were filtered with 250 mm and
100 mm cell strainers. The filtered tissue suspension was passed through a 75 mm filter, after which the remaining glomeruli on the mesh were isolated. Isolated glomeruli were cultured on type I collagen-coated
dishes. Cells were maintained at 37 C, 5% CO2 in RPMI-1640 supplemented with 10% heat inactivated fetal
bovine serum and penicillin-streptomycin, insulin, transferrin, and selenium. After 6 days culture, cells
were dissociated with 0.25% trypsin/EDTA and filtered with a 30mm cell strainer and then centrifuged
(200 g, 5 min). Cell pellets were dissociated with culture media and seeded onto type I collagen
coated dishes and used for experiments. Intracellular proteins were extracted with RIPA buffer (0.05 M
Tris-HCl [pH 7.5], 0.15 M NaCl, 1% v/v Nonidet P-40, 1% w/v Na deoxycholate, and 1% protease inhibitor
cocktail). mRNA was extracted with TRIzol Reagent (Invitrogen) according to the manufacturer’s
instructions.

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters are reported in the Fig. Legends. Immunoblot experiments were performed in triplicate using 3 independent transfections. Luciferase assays were performed in quadruplicate using 4 independent cell cultures. The significance of differences between two groups was assessed using Student’s
unpaired two-tailed t-tests. For three-group comparisons, we used analysis of variance (ANOVA) with Tukey-Kramer post-hoc or Dunnett’s tests. Differences with p values of less than 0.05 were considered statistically significant.
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